At first glance, NeoPharm Inc. (OTC:NEOL) may appear to be just another regular cancer FDA play, but closer inspection reveals a number of key differentiators that may set it apart as an investment option for biotech enthusiasts. First, it has a deep pipeline which targets billions of dollars in market potential, including treatments for: Metastatic Brain Cancer, Metastatic Solid Cancer, Pancreatic Cancer, Glioblastoma Multiforme, and Idiopathic Pulmonary Fibrosis. An undervalued price per share due to the company's inability to meet the NASDAQ requirements, thus leading to a delisting. All the while having a 4Q09 which is bound to reap news and announcements across the board with regards to the ongoing clinical trials. The company's financials certainly took a hit during second quarter 2009, however, what do you expect given that they've had a busier year with regards to clinical and preclinical development testing than ever before. About NeoPharm Inc. NeoPharm has multiple drug candidates in various points of clinical development, including a LEP-ETU Phase II trial for breast and ovarian cancer, a LE-DT Phase I trial, also for various forms of cancer and Cintredekin Besudotox preclinical studies for untreatable brain diseases in humans. The company's robust pipeline has additional indications for Cintredekin Besudotox for idiopathic pulmonary fibrosis, and its product initiatives are funded and progressing as planned. NeoPharm's clinical trials have been structured to capitalize on broader indications of cancer. With a reorganization strategy originally announced in April 2007, NeoPharm has achieved significant cost-savings and put into place an optimal cost structure which enables the company to focus primarily on the development of drug candidates. The company has significantly reduced its cash consumption rate and has resources available to fund current candidates in development into the second quarter of 2010. Key initiatives completed as part of this reorganization include: Annualized cash consumption levels reduced to approximately $5 million Cost structure realigned to optimize the progress of several drug candidates to next strategic event Streamlined organization to include a core team of technical employees to support development activities and ensure regulatory compliance for all drug candidates Formed a new management team with relevant experience and expertise, including Dr. Aquilur Rahman, NeoPharm's co-founder and Chief Scientific Advisor Pipeline NeoPharm is a biopharmaceutical company developing and commercializing drugs for the treatment of various cancers and other diseases using enhanced and innovative drug delivery systems. NeoPharm is focused on providing life-saving and life-enhancing solutions to the drug delivery and oncology markets. The following table summarizes key information about our current drug product candidate pipeline: The drug product candidate which they have advanced the furthest is Cintredekin Besudotox, a tumor-targeting toxin being developed as a treatment for glioblastoma multiforme, or GBM, a deadly form of brain cancer. Glioblastoma multiformes (GBM) is the most common type of malignant primary brain tumor in adults. They are very aggressive, having tentacles that spread and mix with normal brain tissue, damaging the adjacent tissue as they grow uncontrollably in the brain. Treatment success has not significantly changed over the last 20 years, with most patients living less than one year after diagnosis despite aggressive surgery, radiation and chemotherapy. Radiation therapy has been the most effective adjuvant therapy for these tumors, but the inherent resistance to radiation therapy and the risk of damaging the adjacent normal brain tissue limits its overall efficacy. GBM is intrinsically resistant to most chemotherapy and very few drugs cross the natural barrier present in the blood vessels of the brain (blood-brain barrier) which means that even drugs that work in the laboratory and in animals cannot reach the tumor cells within the brain. This unfortunate combination has resulted in only two FDA approved chemotherapy for this type of tumor with two forms of delivery, by vein or by local biodegradable wafers. The impact of these approved therapies increases survival in patients with this deadly tumor by only a few weeks. Clinical Studies They have exclusively licensed Cintredekin Besudotox from the NIH and the FDA, and have been developing this drug product candidate under a Cooperative Research and Development Agreement, or CRADA, with the FDA Center for Biologics Evaluation and Research, or CBER. Cintredekin Besudotox has received orphan drug designation in the US and Europe and FDA has designated it for the fast track drug development program. In addition, Cintredekin Besudotox has been selected to participate in the FDA's Continuous Marketing Application, CMA, Pilot 2 program. They also hold a non-exclusive license to utilize a patented process owned by the U.S. government relating to convection enhanced delivery, or CED, for use with drugs, including Cintredekin Besudotox, in the treatment of gliomas. In early 2007, NeoPharm completed its Phase III clinical trial for Cintredekin Besudotox. Upon review of the trial results with us in March 2007, the FDA concluded that an additional Phase III confirmatory trial would be required prior to acceptance of a potential BLA filing by NeoPharm. In June 2008, NeoPharm signed a letter of intent with a clinical research organization (CRO) with regard to the CRO's engagement to oversee a planned confirmatory Phase III trial for Cintredekin Besudotox. This initial Phase III confirmatory trial was to have the primary objective of overall survival, with a secondary objective of progression-free survival for patients with recurrent GBM against the standard of care. Subsequently, NeoPharm received notification from the Directorate General of Health Services - Office of Drugs Controller General (India) ("DCGI") that it will not at this time grant regulatory approval for NeoPharm to conduct its planned confirmatory IL-13 Phase III trial. In its previous correspondence, the DCGI requested concurrent enrollment of patients in the trial in the USA. In the fourth quarter of 2008, NeoPharm signed a Cooperative Research and Development Agreement ("CRADA") with the National Institute of Neurological Diseases and Stroke ("NINDS"), a part of the National Institutes of Health ("NIH"), for research on a therapeutic agent for untreatable brain diseases in humans. Under the terms of the CRADA, NINDS will deliver IL-13 in conjunction with a surrogate marker via NINDS' patented methodology of Convection Enhanced Delivery ("CED"), which was previously licensed to NeoPharm. NeoPharm will provide its proprietary drug and technical resources to study its effects in various brain cancers in humans. NINDS Institutional Review Board ("IRB") has approved the protocol and NeoPharm has granted NINDS authorization to cross-reference its prior IL-13 IND for the treatment of GBM. IPF - Idiopathic Pulmonary Fibrosis The Company has licensed IL13-PE38 from NIH, FDA, and University of Michigan as a potential therapeutic agent for the treatment of idiopathic pulmonary fibrosis and asthma. Idiopathic pulmonary fibrosis may result from a malfunctioning immune system. Repeated immune-related damage and scarring destroys the elasticity of the lungs, compromising the patients' ability to breathe. Cells initiating the immune response to the lungs over-express IL-13 receptors. Selective destruction of cells presenting IL-13 receptors reduces further damage and improves lung function in animal disease models of idiopathic pulmonary fibrosis. The Company's collaborators have completed extensive preclinical studies in animal models to evaluate the control and reversal of pulmonary fibrosis with this agent. The following slide shows reduced pulmonary fibrosis in mouse studies after treatment with Cintredekin Besudotox. NeoPharm uses novel proprietary lipids and improved procedures to entrap difficult-to-deliver drugs in small, homogeneous, and stable liposomes, which are microscopic membrane-like structures created from lipids (fats). Because tumor cells need to consume large amounts of fat to sustain their rapid growth, they recognize the liposomal drug as a potential source of nutrition. NeoPharm's NeoLipid® innovative system of delivering anticancer drugs to tumors can potentially improve pharmacokinetics and reduce the toxicity of potent drugs, creating an opportunity for more comfortable-to-administer, well tolerated, and safer treatments for patients. NeoLipid® formulations are designed to produce small and homogenous drug particle sizes using simple, easy-to-use (ETU) reconstitutions of lyophilized (or freeze-dried) products with the goal of creating an extraordinarily stable liposomal product.. This is especially important during drug storage, reconstitution and administration to the patient. NeoPharm believes NeoLipid® technology may have applications in a variety of other areas in addition to the drug product candidates in clinical development. Potential advantages of NeoLipid® Drug Delivery Technology: Higher anticancer potency Broader range of drugs Toxicity may be reduced Fewer perceived side effects NeoPharm intends to explore the use of its proprietary NeoLipid® liposomal drug delivery technology in terms of life cycle management, with the goal of extending patent life and/ or modifying the pharmacokinetic profile of existing cancer drugs, and by utilizing the platform to develop new drugs. NeoPharm is aware of several widely used cancer drugs that are nearing patent expiration, as well as other widely used cancer drugs with patents that have expired. When a drug is combined with another agent or delivery system in a novel way, its patent life may be extended. Additionally, while many chemotherapeutic drugs have been effective for the treatment of cancer, these drugs have been limited in their use because of adverse side effects and difficulties in administration. NeoPharm's NeoLipid® drug delivery technology may increase the usefulness of these compounds as improved anti-cancer treatments. Finally, NeoPharm believes that its liposomal drug delivery technology may provide a platform for the development of novel therapeutic agents for cancer drug development. Intellectual Property NeoPharm owns exclusive rights to the NeoLipid® Technology and Tumor-Targeting platforms. The Company has entered into an agreement with the National Institute of Health (NIH) and the Food and Drug Administration (FDA) to license rights to develop and commercialize Cintredekin Besudotox for cancer indications. The Company has also entered into an agreement with the NIH to license rights to develop and commercialize Cintredekin Besudotox for idiopathic pulmonary fibrosis and asthma. NeoPharm has entered into agreements with Georgetown University to license rights to develop and commercialize the drug product candidates in our NeoLipid® Platform, including LEP-ETU and LE-rafAON. NeoPharm actively seeks strategic collaboration with biotechnology and pharmaceutical companies to enhance the growth and market opportunity beneficial to both companies. NeoPharm continues to build its pipeline rapidly and advance existing drugs to the market, fulfilling its commitment in bringing breakthrough therapeutics to patients. The Company is interested to discuss licensing and co-development opportunities related to drugs in its pipeline or development of new or improved drugs. FDA Updates ( Provided by BioMedreports' FDA Calendar ) Technical Chart Analysis Today, September 29th, NEOL took a peek above the middle trend-line (Blue dashed line on the chart) of a very well established price channel and may be giving an indication of its readiness to move up to the top of the channel and beyond. The current price channel (Blue lines on the chart) has been in control for a year now and the price has spent the past 8 months moving through and up the lower half of the channel. In the last 4 months, the price has clearly been consolidating since it jumped above the daily 200 SMA (Yellow line on the chart) back in May. Also, during this time, the daily 100 SMA (Orange line on the chart) crossed up and over the 200 SMA and both averages are currently trending up (strong bullish signals). Today’s move looks to be the third attempt this year to break that middle trend-line and it is very common that the third time usually is the charm. Factor in the heavy volume (grey bars) under the strong green candle today and there is certainly an increase in interest and building of momentum that will continue to push the price up the channel. It’s good to keep in the back of your mind that there appears to be a level of strong support/resistance at .50 cents, established throughout 2008, and this corresponds very closely with the ¾ trend-line of the current price channel (Red circle on chart). When the price breaks this level, it could easily expand the top of the current price channel and seek the next level of support/resistance around .80 cent Overall Sentiment With the Company having drawn down the full amount of the credit line and now projecting that it will have sufficient cash to fund its operations into 2010, NeoPharm has set itself nicely for a bright open in 2010, following much anticipated pending news for 4Q09. With clinical trials continuing to impress, volume rising with each passing day, and a cheap pps due to the recent delisting -- expect NeoPharm to bounce back and make some headlines with its upcoming groundbreaking products and treatments. ———– Disclosure: Long NEOL By reading StocksHaven Investments company profiles you agree to the disclaimer, and thereby will not hold Michael Vlaicu accountable for any transactions or decisions you make. It is up to you to do your own due diligence. StocksHaven Investments is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies, unless otherwise stated.

As I wrote in mid-October as part of a commercial / clinical update article on MuGard, the $1.55 million in cash / equivalents for Access Pharma (OTC: ACCP.OB) as of mid-August would normally be a major concern for most companies. However, it should be noted the cash burn rate for the Company is very low (i.e. $241,000 per month or about $0.72M per quarter through 1H09). Also, Mr. Davis confirmed at the time of my previous article that the current liquidity is sufficient to fund operations through mid-2010 without even considering any MuGard royalties from Europe or the potential for upfront cash in a North American licensing deal for this product or any others in development such as oral insulin.

Since SCO Capital also has the perspective a major investor / shareholder in Access, additional equity capital from institutional investors should be considered a positive development for the reasons outlined below. A conservative capital raise of $10-15 million would be reasonable considering a fully diluted market cap of approximately $70 million at this time, which would be about half of the $25 million maximum offering of common stock and warrants in the SEC S-1 filing that was made on 10/27/09.

1.) to secure a stock listing on AMEX or NASDAQ (to address positive net equity requirements which arise due to previously applied accounting standards for in-process R&D from acquisitions);

2.) to provide a stronger negotiating position for licensing the rights to MuGard in North America and the pending U.S. commercial launch in conjunction with the contract manufacturing agreement with Accupac and the eMarketing agreement with iMedicor;

3.) to fund further clinical development and new studies for thiarabine and ProLindac.

Click here to visit the ProActive News Room landing page for Access, which includes a compilation of digital media coverage links, report downloads, news feeds, and recent CEO video interview conducted by OneMedPlace.com, including a link to the SEC filing from today.

On 10/27/09, BioSphere Medical (NASDAQ: BSMD) announced the submission to the FDA of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere's QuadraSphere Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer. Provided that the FDA accepts the planned clinical protocol, the Company plans to begin enrolling patients into the study within 60 days of FDA approval. The proposed investigation will be a prospective, randomized, double-blinded clinical trial conducted at approximately 15 sites in the U.S., European Union and Brazil.

The clinical trial will focus on treating patients with advanced hepatocellular carcinoma (HCC), also known as primary liver cancer, and will compare QuadraSphere with doxorubicin against conventional transarterial chemoembolization (cTACE) with doxorubicin. BioSphere anticipates that patient enrollment will take approximately 12 months, and that it will file a premarket approval application (PMA) with the FDA approximately 12 months after the final patient is enrolled. The Company expects to fund trial costs from current working capital and cash flow from operations.

On 10/27/09, CryoLife (NYSE: CRY) announced that the FDA has granted approval for the company's Investigational Device Exemption (IDE) to conduct a human clinical trial for its BioFoam Surgical Matrix protein hydro-gel technology. BioFoam will be used to help seal liver parenchymal tissue when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. The approved IDE is for a prospective, multicenter, randomized feasibility study evaluating safety outcomes of BioFoam as compared to a standard topical hemo-static agent. The feasibility investigation will be conducted at two investigational sites and will enroll 20 eligible subjects with 10 subjects in each treatment group.

CryoLife now will seek approval from the U.S. Department of Defense (DoD), which will be the final step necessary to begin this trial. CryoLife is currently conducting a 60-patient controlled clinical launch of BioFoam at up to six centers in the United Kingdom, Germany, France and Italy. Upon successful completion of the feasibility study, and subsequent FDA and DoD approvals, a follow-on prospective, multicenter, randomized, controlled pivotal study will be conducted. It is currently anticipated that the pivotal investigation will enroll a total of 164 eligible subjects, 82 subjects in each treatment group across a maximum of 10 investigational sites.

On 10/27/09, NeoPharm (OTC: NEOL.PK) announced that it submitted a Phase 2 protocol to the FDA for LE-DT for locally advanced or metastatic pancreatic cancer patients. If the study is approved, NeoPharm expects to enroll 40 patients in the Phase 2 trial at 3-4 locations in the U.S. and Europe. NeoPharm has completed enrollment in a multi-center Phase 1 clinical trial for LE-DT (Liposomal Encapsulated Docetaxel) (a liposomal delivery form of Taxotere) for the treatment of patients with metastatic solid tumors and expects to release preliminary findings for the Phase 1 LE-DT study during 4Q09.

Based upon the preliminary results from its Phase I trial for LE-DT for the treatment of patients with metastatic solid tumors, the Company is planning a Phase 2 study of LE-DT in hormone refractory metastatic prostate cancer patients. This open-label, Phase 2 study will be designed to determine the antitumor effect as defined by the serum Prostate Specific Antigen (PSA) levels, disease response, progression free survival, and quality of life in patients with metastatic prostate cancer. NeoPharm is also developing a two-arm protocol, subject to regulatory approval, for advanced pancreatic cancer patients to compare the clinical effectiveness of LE-DT against 5FU or Xeloda.

Disclosure: Long ACCP.OB

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced it is scheduled to present at the Oppenheimer 20th Annual Healthcare Conference being held at the Waldorf-Astoria Hotel in New York City, New York.

 

PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

 

Ligand Pharmaceuticals Inc., (NASDAQ:LGND) and Metabasis Therapeutics, Inc. (NASDAQ:MBRX) announced they have entered into a definitive merger agreement under which Ligand will acquire all of the outstanding shares of Metabasis.

 

Geron Corporation (NASDAQ:GERN) will announce its financial results for the 2009 third quarter on Thursday, October 29, 2009, after the closing of the equity market.

 

Life Technologies Corporation (NASDAQ:LIFE) announced results for its third quarter ended September 30, 2009.

 

BioSphere Medical, Inc. (NASDAQ:BSMD) – the leader in the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy –announced the submission to the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) application for a clinical trial for the use of BioSphere’s QuadraSphere® Microsphere product (QuadraSphere) to deliver the chemotherapeutic agent doxorubicin for the treatment of primary liver cancer.

 

International Stem Cell Corporation (OTC:ISCO) and Reproductive Medicine Associates of New York (RMA of New York) have show immature, unfertilized human eggs can be used to create “parthenotes” from which human parthenogenetic stem cell lines may be derived.

 

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, announced the Company will be presenting at the Oppenheimer 20th Annual Healthcare Conference at 3:55 p.m. EST on November 3, 2009, at the Waldorf Astoria in New York City.

 

Helicos BioSciences Corporation (NASDAQ:HLCS) announced its operational, technical and scientific highlights for the quarter ended September 30, 2009.

 

PolyMedix, Inc. (OTC:PYMX), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders, has completed a second successful clinical study of its anticoagulant reversing agent, PMX-60056.

 

ImmunoCellular Therapeutics, Ltd. (OTC: IMUC), a biotechnology company which is focused on the development of novel immune-based cancer therapies, announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM).

 

Columbia Laboratories, Inc. (Nasdaq: CBRX) announced Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. will present at the upcoming Oppenheimer 20th Annual Healthcare Conference.

 

Alkermes, Inc. (NASDAQ: ALKS) announced the initiation of a phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the opioid agonist effects on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC).

 

POZEN Inc. (NASDAQ: POZN) announced the results of a Phase I study that showed a novel, investigational combination of enteric-coated aspirin (EC-ASA) an immediate-release omeprazole known as PA65020, is associated with a significantly decreased risk of GI mucosal damage compared to analgesic doses (650 mg twice daily) of over-the-counter enteric-coated aspirin (EC-ASA) in healthy adults treated for one month.

 

NeoPharm, Inc. (OTC:NEOL) announced it has submitted a Phase II protocol o the FDA for the study of liposome entrapped docetaxel (LE-DT), novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.

 

OSI Pharmaceuticals, Inc. (NASDAQ:OSIP) announced OSI Management will present at the Oppenheimer Healthcare Conference in New York, NY on Tuesday, November 3, 2009 at 3:20pm (Eastern Time) and will provide an overview on the Company’s product portfolio and business developments.

 

Manhattan Scientifics (OTCBB: MHTX) and Senior Scientific, LLC announced they have begun cooperative work to commercialize Senior Scientific’s nano medicine cancer detection technology.

 

Inhibitex, Inc. (NASDAQ: INHX) announced it would host a conference call on Friday, November 6, 2009 at 9:00 a.m. EDT to review the Company’s financial results for the third quarter ended September 30, 2009 and provide an update on recent corporate developments.

 

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems (OTC:RHHBY) in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

 

Revolutions Medical Corporation (OTCBB:RMCP), producers of the RevVac safety syringe, RevColor, RevDisplay and Rev3D MRI Technology, announced CEO Ron Wheet has been featured in the popular AllPennyStocks.com Spotlight series, produced by TheNewsWire.ca.

 

Rockwell Medical (NASDAQ:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that it has unveiled a new corporate identity consisting of a new logo, Company name and website.

 

Unilife Medical Solutions (OTC:UNIFF) announced it has commenced the filing of international trademarks for Unifill™, which will become the market brand for its portfolio of ready-to-fill safety syringes.

 

Orexigen® Therapeutics, Inc. (Nasdaq:OREX) announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trial of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity.

 

Cytori Therapeutics, Inc., (NASDAQ:CYTX) will present and provide a webcast of its corporate presentation at the 2009 BIOCOM Investor Conference at 1:00 PM PDT on Tuesday, October 27, 2009.

 

King Pharmaceuticals, Inc. (NYSE:KG) announced it has licensed from Merck Santé S.A.S., an affiliate of Merck KGaA, Darmstadt, Germany, the exclusive rights to market and sell CYANOKIT® 5 g (hydroxocobalamin for injection) ANTIDOTE in the U.S. CYANOKIT® is indicated for the treatment of known or suspected cyanide poisoning, typically caused by smoke inhalation from fires.

 

McKesson Corporation (NYSE:MCK) reported revenues for the second quarter ended September 30, 2009 were $27.1 billion compared to $26.6 billion a year ago.

 

Please note a change to the Merge Healthcare Inc., (NASDAQ:MRGE) third quarter 2009 earnings call. The call, which was previously scheduled for 4:15 PM EDT on Thursday, October 29, 2009, will now be held at 9:00 AM EDT.

 

PPD, Inc. (Nasdaq:PPDI) reported its financial and operating results for the third quarter ended September 30, 2009.

 

Total Nutraceutical Solutions, Inc. (OTC:TNUS), announced the company has formulated and will launch a unique natural whole food mushroom-based Vitamin D supplement.

 

Osteologix, Inc. (OTC:OLGX) announced Philip J. Young, President and CEO of Osteologix, will present a corporate overview and update at the 8th Annual Bio Investor Forum being held this week at the Palace Hotel in San Francisco, California.

 

3SBio Inc. (Nasdaq:SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced it will release financial results for the third quarter ended September 30, 2009 after the US market closes on Thursday, November 12, 2009.

 

 

TomoTherapy Inc., (NASDAQ:TOMO) announced four recipients of grants from the first round of its 2009-2010 TomoTherapy® Clinical Investigation Partnership Program.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.

Curis, Inc. (NASDAQ:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, reported its financial results for the third quarter ended September 30, 2009.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG), a biopharmaceutical company focused on the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease, reported unaudited consolidated financial results for the third quarter and nine months ended September 30, 2009.

King Pharmaceuticals, Inc. (NYSE:KG) announced the Company plans to report financial results for the third quarter ended September 30, 2009 prior to the market open on Thursday, November 5, 2009.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) announced it will sponsor a conference call to discuss its financial results for the quarter ended September 30, 2009.

Genta Incorporated (OTC:GETA) announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma.

Targacept, Inc. (NASDAQ:TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, announced it will report financial results for the third quarter ended September 30, 2009 on Thursday, November 5, 2009, after the U.S. financial markets close.

Inhibitex, Inc. (Nasdaq:INHX) reported the completion of its previously announced $23 million private placement of common stock and warrants.

Medidata Solutions (Nasdaq:MDSO), a leading global provider of hosted clinical development solutions, announced it will release its third quarter 2009 financial results following the close of the market on Thursday, November 12, 2009.

NPS Pharmaceuticals, Inc. (Nasdaq:NPSP) announced it plans to report its third quarter 2009 financial results on Wednesday, November 4, 2009 at approximately 4:30 p.m. ET.

NeoPharm, Inc. (Other OTC:NEOL.PK) announced the appointment of Dr. Aquilur Rahman to the position of President and CEO of the Company, succeeding Laurence P. Birch, who is stepping down as President and CEO to pursue other opportunities.

ArQule, Inc. (NASDAQ:ARQL) announced it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time.

Phase Forward (NASDAQ:PFWD), a leading provider of data management solutions for clinical trials and drug safety, announced a multi-year contract with renowned eye health company Bausch & Lomb.

Allergan, Inc. (NYSE:AGN) announced operating results for the quarter ended September 30, 2009. Allergan also announced its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

Medidata Solutions (Nasdaq: MDSO), a leading global provider of hosted clinical development solutions, announced members of its executive team will deliver the following presentations at key industry events in November:  1st DIA China Annual Meeting November 2-3, 2009, Beijing, China.

XenoPort, Inc. (Nasdaq:XNPT) announced it will release its third quarter financial results on November 3, 2009 at approximately 4:00 p.m. Eastern Time.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced positive results from Phase 1 studies of CDX-1307 in patients with advanced epithelial cancers, including breast, colon, bladder and pancreatic cancer.

Students at The Pennington School will have an unprecedented opportunity this year to conduct hands-on, high-tech science projects, thanks to sophisticated science equipment donated by Bristol-Myers Squibb Company (NYSE:BMY).

PerkinElmer, Inc. (NYSE:PKI), a global leader focused on improving the health and safety of people and the environment, reported financial results for the third quarter ended October 4, 2009.

Exelixis, Inc. (Nasdaq:EXEL) reported financial results for the third quarter ended September 30, 2009.

PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, reported the results of its third quarter of 2009 and nine months ended September 30, 2009.

Human Genome Sciences, Inc. (Nasdaq:HGSI) announced financial results for the quarter ended September 30, 2009, and provided highlights of recent key developments.

ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, announced financial results for the three-month period ended September 30, 2009 – the first quarter of the Company’s 2010 fiscal year (1QFY10).

Dynavax Technologies Corporation (Nasdaq:DVAX) announced the first clinical data for HEPLISAVTM investigational hepatitis B vaccine in chronic kidney disease patients.

Cumberland Pharmaceuticals Inc. (Nasdaq:CPIX) and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, announced they have entered into an exclusive partnership for the commercialization of Caldolor® (ibuprofen) Injection in Australia and New Zealand.

Synovis Life Technologies, Inc. (Nasdaq:SYNO), a leading biomaterial and surgical products company, will present at the Oppenheimer 20th Annual Healthcare Conference at 3:30 p.m. CT (4:30 p.m. ET) on Tuesday, Nov. 3, 2009, at the Waldorf Astoria Hotel in New York City.

Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Oppenheimer 20th Annual Healthcare Conference.

Depomed, Inc. (NASDAQ:DEPO) reported financial results for the third quarter ended September 30, 2009.

Perrigo Company (Nasdaq:PRGO) announced its Board of Directors declared a quarterly dividend of $0.0625 per share, payable on December 15, 2009 to shareholders of record on November 27, 2009.

Transgenomic Inc. (OTC:TBIO) announces the following Webcast: What: Transgenomic Inc. Third Quarter 2009 Earnings Release Conferece Call When: Thursday, November 5, 2009 @ 5:00 p.m. Eastern Where: http://www.transgenomic.com/events.asp?id=6 How:Live over the Internet -- Simply log on to the web at the address above. Contact:Investor Relations, 402-452-5400

Hospira, Inc. (NYSE:HSP) celebrates the 25th anniversary of its market-leading patient-controlled analgesia (PCA) infusion system. Introduced in 1984, Hospira's PCA was the first pump of its kind, revolutionizing pain management.

IntriCon Corporation (NASDAQ:IIN), a designer, developer, manufacturer and distributor of body-worn medical and electronics devices, announced it will be presenting at the 2009 TechAmerica AeA Classic Financial Conference on Tuesday, Nov. 3, 2009, at 9:05 a.m. PT.

Pfizer Inc. (NYSE:PFE) announced its Board of Directors has approved giving shareholders an advisory vote on executive compensation.

Merck & Co., Inc. (NYSE:MRK) and Schering-Plough Corporation (NYSE: SGP) announced they have received clearance from the U.S. Federal Trade Commission (FTC), the Swiss Competition Commission and the Canadian Competition Bureau for their proposed merger.

CEO Thomas A. Moore of Advaxis, Inc., (OTC:ADXS), the live, attenuated Listeria monocytogenes (Lm) biotechnology company, will present at the 8th Annual BIO Investors Forum at the Grand Hotel in San Francisco, CA.

CNS Response, Inc. (OTC:CNSO) announced CEO George Carpenter will be conducting a conference call and simultaneous web conference to discuss top-line study results in a 12-week trial for patients with depression treatment failure on Tuesday, November 3, at 8:00 a.m. Pacific (PST), 11:00 a.m. Eastern (EST). Joining Mr. Carpenter will be CNS Response President and CMO Daniel Hoffman, M.D., and Charles DeBattista, M.D., Stanford University School of Medicine.

China Biopharmaceuticals Holdings, Inc. (OTC:CHBP), an integrated bio-pharmaceutical company, based in the People's Republic of China, announced its shareholders have approved the acquisition of CHBP by NeoStem, Inc. (NYSE AMEX: NBS) by an overwhelming vote in favor of approximately 80% of all issued and outstanding shares.

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq:ONXX) announced more than 25 studies evaluating the use of Nexavar® (sorafenib) tablets in liver cancer will be presented at The Liver Meeting®, the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD).

MinuteClinic, the retail health care division of CVS Caremark (NYSE:CVS), and Allina Hospitals & Clinics of Minnesota and western Wisconsin have formed a partnership to pursue collaborative activities which will focus on enhancing high-quality health care services in the communities they serve.

VeriChip Corporation (NASDAQ:CHIP) announced its Chairman and Chief Executive Officer, Scott R. Silverman, will present at the ID World International Congress in Milan, Italy, which runs from November 3-5, 2009, and is the world's leading symposium on the future directions of identification technology.

ArQule, Inc. (NASDAQ:ARQL) announced it will report its financial results for the third quarter of 2009 in a press release to be issued on Thursday, November 5, 2009 at 7:00 a.m. eastern time.

At first glance, NeoPharm Inc. (OTC:NEOL) seems like just another regular cancer FDA play, however upon closer inspection there are numerous key facts that set it apart, making it a valuable investment option for biotech enthusiasts. Here at StocksHaven Investments, we don’t just like this company — we like it a lot! Firstly, a deep pipeline which targets billions of dollars in market potential, including treatments for: Metastatic Brain Cancer, Metastatic Solid Cancer,[More...]